CVRx, Inc.

CVRx, Inc. (CVRX) priced its initial public offering on Jul 1, 2021 at $18.00 per share, above its $15.00–$17.00 range, raising $126M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $347.3M. J.P. Morgan was lead-left underwriter, joined by Piper Sandler, William Blair and Canaccord Genuity.

CVRx, Inc. is a commercial-stage medical device company making neuromodulation therapy for cardiovascular disease. Its BAROSTIM NEO device delivers Baroreflex Activation Therapy through electrical pulses to the carotid artery and is indicated for heart failure with reduced ejection fraction.

Status

IPO

Ticker

CVRX

Exchange

Nasdaq Global Select

Priced

Jul 1, 2021

IPO price

$18.00

Price range

$15.00–$17.00

Raised

$126M

Market cap at IPO price

$347.3M

First filed

Jun 4, 2021

Underwriters

J.P. Morgan, Piper Sandler, William Blair and Canaccord Genuity

Sector

Healthcare

Country / state

MN

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.